Ocriplasmin for Treatment of Vitreomacular Traction and Macular Hole A Systematic Literature Review and Individual Participant Data Meta-Analysis of Randomized, Controlled, Double-Masked Trials

Ocriplasmin is used to treat vitreomacular traction (VMT), with or without full-thickness macular hole (MH). We systematically reviewed the evidence on ocriplasmin's effect on vitreomacular adhesion resolution (VMAR), MH closure, vitrectomy, and best-corrected visual acuity (BCVA) and investigated the effect of baseline covariates on outcome. We applied individual participant data meta-analyses to the entire population and to subgroups defined by MH or epiretinal membrane (ERM) presence. Safety data were pooled and tabulated.

Source: Survey of Ophthalmology - September 1, 2021 Category: Opthalmology Authors: Timothy L. Jackson, Julia Haller, Koenraad H. Blot, Luc Duchateau, Benedicte Lescrauwaet Source Type: research